Work

Avatrombopag for the treatment of patients with chemotherapy‐induced thrombocytopenia: A case series

Year: 2024

Type: article

Abstract: Management of chemotherapy-induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management. A phase III trial of avatrombopag (AVA) demonstrated increased platelet counts (PC) in patients with solid tumours experiencing CIT. To complement those findings, this case series of six patients with solid tumours and CIT is presented. Results from these cases support the clinical benefit of AVA in improving PC and reducing the impact of CIT on tumour treatment, allowing continued therapy without dose reduction or treatment interruption.

Source: British Journal of Haematology

DOI: 10.1111/bjh.19797

Authors: Robert Galamaga, Stephanie Johnston, Cassaundra Acosta

Language: English

Topic: Platelet Disorders and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,940

OpenAlex ID: W4403636743

FWCI: 1.875

Cites: 8

Cited by: 7

Related to: 10